Clinical Trials Logo

Dry Eye Syndromes clinical trials

View clinical trials related to Dry Eye Syndromes.

Filter by:

NCT ID: NCT01743729 Completed - Dry Eye Disease Clinical Trials

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Start date: December 7, 2012
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye.

NCT ID: NCT01742884 Completed - Clinical trials for Moderate Dry Eye Syndrome

Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz

Start date: December 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if Thealoz is effective in Dry Eye Syndrome exposed to controlled adverse environmental conditions.

NCT ID: NCT01733992 Completed - Clinical trials for Keratoconjunctivitis Sicca

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Start date: November 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of R348 eye drops in patients with dry eye disease.

NCT ID: NCT01733745 Completed - Dry Eye Syndrome Clinical Trials

SYSTANE® Family - Meibomian Deficiency

M-12-077
Start date: February 2013
Phase: N/A
Study type: Interventional

The purpose of this study was to assess the efficacy of the SYSTANE® family of products (SYSTANE® Lid Wipes, SYSTANE® BALANCE Lubricant Eye Drops, and SYSTANE® Vitamins) on meibomian gland functionality in subjects with lipid deficiency related to evaporative dry eye as compared to the standard of care warm compresses.

NCT ID: NCT01733732 Completed - Dry Eye Syndrome Clinical Trials

SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers

Start date: March 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the ability of SYSTANE® BALANCE and SYSTANE® Gel to improve comfort in subjects with dry eyes.

NCT ID: NCT01718028 Completed - Dry Eye Clinical Trials

The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects

Start date: September 2012
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate the ability of SYSTANE® BALANCE dosed 4 times a day for 30 days to increase non-invasive tear film break up time over baseline, compared to a saline control, in dry eye subjects with lipid deficiency.

NCT ID: NCT01711424 Completed - Dry Eye Syndromes Clinical Trials

An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease

Start date: September 2012
Phase: N/A
Study type: Observational

This is an observational study of OPTIVE PLUS® in patients with dry eye disease in a routine clinical setting. Treatment decisions are made by the physician and reflect the physician's current standard of care.

NCT ID: NCT01692145 Completed - Dry Eye Syndromes Clinical Trials

A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndromes.

NCT ID: NCT01688726 Completed - Dry Eye Syndrome Clinical Trials

Evaluation of SYSTANE® BALANCE in Dry Eye Subjects With Lipid Deficiency

Start date: December 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the repeated use of SYSTANE® BALANCE on stabilizing the tear film of dry eye patients with an unstable tear film.

NCT ID: NCT01684852 Completed - Dry Eye Syndromes Clinical Trials

Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution

Start date: May 2012
Phase: N/A
Study type: Observational

This is a comparative, open label, parallel group, non interventional study to further demonstrate the efficacy and tolerability of BAT04. In addition the efficacy and safety shall be compared to Hyaluronic acid (HA)-Product. The patient applies BAT04 or HA-Product according to the instructions for use six times daily in both eyes over a period of 28 days. Response to treatment is recorded at day 28.